Simcere’s Culevibart Wins NMPA Approval as China’s RSV Prevention Monoclonal Antibody Yingmule
Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity